David Francisco
CIK: 0001846282
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Organogenesis Holdings Inc.
Discretionary Trading P&L
Holdings
Transaction History (14 total)
- Feb 18, 2026ORGO
Organogenesis Holdings Inc.
Award(A)Direct44K shares- - Feb 18, 2026ORGO
Organogenesis Holdings Inc.
Tax Payment(F)Direct14.7K shares at avg. $3.84$56K - Feb 18, 2026ORGO
Organogenesis Holdings Inc.
Award(A)Direct43.6K shares- - Feb 18, 2026ORGO
Organogenesis Holdings Inc.
Tax Payment(F)Direct14.5K shares at avg. $3.84$56K - Feb 18, 2026ORGO
Organogenesis Holdings Inc.
Award(A)Direct195.3K shares- - Feb 15, 2026ORGO
Organogenesis Holdings Inc.
Tax Payment(F)Direct21.4K shares at avg. $3.73$80K - Feb 15, 2026ORGO
Organogenesis Holdings Inc.
Tax Payment(F)Direct13.4K shares at avg. $3.73$50K - Feb 15, 2026ORGO
Organogenesis Holdings Inc.
Tax Payment(F)Direct13.8K shares at avg. $3.73$51K - Feb 15, 2026ORGO
Organogenesis Holdings Inc.
Tax Payment(F)Direct3.9K shares at avg. $3.73$15K - Feb 19, 2025ORGO
Organogenesis Holdings Inc.
Award(A)Direct165.2K shares- - Feb 16, 2025ORGO
Organogenesis Holdings Inc.
Tax Payment(F)Direct804 shares at avg. $3.70$3K - Feb 15, 2025ORGO
Organogenesis Holdings Inc.
Tax Payment(F)Direct3K shares at avg. $3.70$11K - Feb 15, 2025ORGO
Organogenesis Holdings Inc.
Tax Payment(F)Direct19.5K shares at avg. $3.70$72K - Feb 15, 2025ORGO
Organogenesis Holdings Inc.
Tax Payment(F)Direct11.8K shares at avg. $3.70$44K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 18, 2026 | ORGO Organogenesis Holdings Inc. | Award(A) | 44,040 | - | $0 | Direct |
| Feb 18, 2026 | ORGO Organogenesis Holdings Inc. | Tax Payment(F) | 14,687 | $3.84 | $56,398 | Direct |
| Feb 18, 2026 | ORGO Organogenesis Holdings Inc. | Award(A) | 43,602 | - | $0 | Direct |
| Feb 18, 2026 | ORGO Organogenesis Holdings Inc. | Tax Payment(F) | 14,541 | $3.84 | $55,837 | Direct |
| Feb 18, 2026 | ORGO Organogenesis Holdings Inc. | Award(A) | 195,312 | - | $0 | Direct |
| Feb 15, 2026 | ORGO Organogenesis Holdings Inc. | Tax Payment(F) | 21,412 | $3.73 | $79,867 | Direct |
| Feb 15, 2026 | ORGO Organogenesis Holdings Inc. | Tax Payment(F) | 13,369 | $3.73 | $49,866 | Direct |
| Feb 15, 2026 | ORGO Organogenesis Holdings Inc. | Tax Payment(F) | 13,769 | $3.73 | $51,358 | Direct |
| Feb 15, 2026 | ORGO Organogenesis Holdings Inc. | Tax Payment(F) | 3,898 | $3.73 | $14,540 | Direct |
| Feb 19, 2025 | ORGO Organogenesis Holdings Inc. | Award(A) | 165,156 | - | - | Direct |
| Feb 16, 2025 | ORGO Organogenesis Holdings Inc. | Tax Payment(F) | 804 | $3.70 | $2,975 | Direct |
| Feb 15, 2025 | ORGO Organogenesis Holdings Inc. | Tax Payment(F) | 2,960 | $3.70 | $10,952 | Direct |
| Feb 15, 2025 | ORGO Organogenesis Holdings Inc. | Tax Payment(F) | 19,528 | $3.70 | $72,254 | Direct |
| Feb 15, 2025 | ORGO Organogenesis Holdings Inc. | Tax Payment(F) | 11,765 | $3.70 | $43,531 | Direct |
1-14 of 14 transactions
About Francisco David
Francisco David (SEC CIK 0001846282) files insider reports with the SEC as Chief Financial Officer of Organogenesis Holdings Inc. (ORGO).
Signal8 holds 5 ownership filings by Francisco David, all Form 4s, filed between Feb 19, 2025 and Mar 3, 2026. Those filings report 14 transactions, from Feb 15, 2025 to Feb 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Francisco David's filings is in CANTON, MA.
Recent filings by Francisco David
- Feb 18, 2026: Grant or award of ORGO shares (Form 4, code A).
- Feb 18, 2026: Tax withholding of ORGO shares (Form 4, code F).
- Feb 18, 2026: Grant or award of ORGO shares (Form 4, code A).
- Feb 18, 2026: Tax withholding of ORGO shares (Form 4, code F).
- Feb 18, 2026: Grant or award of ORGO shares (Form 4, code A).
Other insiders filing for Organogenesis Holdings Inc. (ORGO)
- Grow Brian, Chief Commercial Officer
- Leibowitz Arthur S, Director
- Driscoll Michael Joseph, Director
- Cavorsi Robert, Vice President, Strategy
- Montecalvo Antonio S., Vice President, Health Policy
- Gillheeney Gary S., President and CEO